Has Oscar finally figured out its health insurance business?

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.)

The last two years weren’t kind to the venture-backed insurance startups who went public in 2021. Clover Health left a program that was a key part of its growth story and focused on profitability instead. Bright Health exited the health insurance business altogether. And after years of posting losses, Oscar Health raised prices and brought on insurance veteran Mark Bertolini as CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

EC approves Roche’s PiaSky for PNH treatment

Roche’s PiaSky is the first monthly subcutaneous therapy for PNH approved in the European Union. Credit: Poetra.RH/Shutterstock. The European Commission (EC) has approved Roche’s recycling

August 27, 2024

Factor D Inhibitor Wins Approval for PNH With Extravascular Hemolysis

The FDA approved the oral factor D inhibitor danicopan (Voydeya) as an add-on therapy to treat extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH),

April 5, 2024

Ohio State study reveals bacterial defense mechanism against phages

One of the many secrets to bacteria’s success is their ability to defend themselves from viruses, called phages, that infect bacteria and use their cellular

April 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.